Growth Hormone in Obese Cases With Covid-19

ClinAmygate

Status and phase: Withdrawn; Phase 4

Conditions: Covid19

Treatments: Drug: Growth Hormone; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT04532554

PR0015

Details and patient eligibility

About

The use of growth hormone in obese cases with COVID-19 may help them to recover earlier.

Full description

It is well known that lymphoid organs such the thymus, the spleen and peripheral blood produce growth hormone (GH) and GH receptor is expressed on different subpopulations of lymphocytes. Many in vitro and in animal studies demonstrate an important role of GH in immunoregulation. GH stimulates T and B cells proliferation and immunoglobulin synthesis, enhances the maturation of myeloid progenitor cells and is also able to modulate cytokine response.

The use of growth hormone in obese cases with COVID-19 may help them to recover earlier.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Obese with BMI > 30

Exclusion criteria

• History of hypersensitivity to GH

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

0 participants in 2 patient groups, including a placebo group

Growth hormone

Experimental group

Description:

Recombinant GH will be used for those patients

Treatment:

Drug: Growth Hormone

Placebo

Placebo Comparator group

Description:

Saline will be used

Treatment:

Drug: Placebo